What is the clinical evidence from this study?

Study design: RCT. Population: Experimental atherosclerosis and restenosis after angioplasty. Intervention: AZ-1 monoclonal antibody vs. Saline infusion. Primary outcome: Mean angiographic minimum luminal diameter.

What does this research mean for the field?

Glycoprotein IIb/IIIa receptor inhibition using the monoclonal antibody AZ-1 does not reduce restenosis or neointimal proliferation after balloon angioplasty in a rabbit model of atherosclerosis. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

August 1, 1994Circulation ResearchOpen Access

Preparation, characterization, and evaluation of a monoclonal antibody against the rabbit platelet glycoprotein IIb/IIIa in an experimental angioplasty model.

View Full Paper

Ask AI

Bookmark

Key result

AZ-1 infusion fails to improve minimum luminal diameter after balloon angioplasty in rabbits.

Why the study?

Platelet deposition at balloon angioplasty sites is believed to contribute to restenosis, but the effect of platelet inhibition on vascular injury response is unclear.

Does monoclonal antibody AZ-1 against platelet glycoprotein IIb/IIIa prevent restenosis after balloon angioplasty in a rabbit model of atherosclerosis?

Population

42 vessels in a rabbit model of experimental atherosclerosis

Comparison

Monoclonal antibody AZ-1 infusion vs saline infusion

Design

Randomized preclinical experimental angioplasty study

Follow-up

28 days

Authors

MAMichael AzrinInterventional / Structural Cardiology FLFrederick S. LingUniversity of Rochester Medical Center QCQi ChenZunyi Medical University

Discussion

Member takes

Implication

AZ-1 shows no benefit in rabbit restenosis model; leaves open any role in human post-angioplasty care.

Study Design

Type

RCT

Structured PICO

Does monoclonal antibody AZ-1 against platelet glycoprotein IIb/IIIa prevent restenosis after balloon angioplasty in a rabbit model of atherosclerosis?

Population

Rabbit model of experimental atherosclerosis undergoing balloon angioplasty, with outcomes evaluated in 42 vessels at 28 days.

Intervention

Monoclonal antibody AZ-1 (against rabbit platelet glycoprotein IIb/IIIa) administered as either a single infusion of 0.5 mg/kg before angioplasty, or 0.6 mg/kg before angioplasty followed by a second infusion of 0.6 mg/kg 72 hours later.

Comparator

Infusion of saline.

Outcome

Mean angiographic minimum luminal diameter at 28 days after angioplasty.surrogate

Potent platelet inhibition with a monoclonal antibody against glycoprotein IIb/IIIa did not reduce restenosis after balloon angioplasty in an experimental rabbit model.

Cite This Study

Azrin et al. (1994) conducted an RCT in Experimental atherosclerosis and restenosis after angioplasty. AZ-1 monoclonal antibody vs. Saline infusion was evaluated on Mean angiographic minimum luminal diameter. Infusion of the AZ-1 monoclonal antibody did not significantly improve mean angiographic minimum luminal diameter 28 days after balloon angioplasty in a rabbit model of atherosclerosis.

synapsesocial.com/papers/6ab60d984a008ef1744c4f41 https://doi.org/10.1161/01.res.75.2.268

Topics

Dual antiplatelet therapy

View Full Paper

Ask AI

Bookmark

Preparation, characterization, and evaluation of a monoclonal antibody against the rabbit platelet glycoprotein IIb/IIIa in an experimental angioplasty model.

Discussion

Member takes

Implication

Study Design

Structured PICO

Cite This Study

Topics

Preparation, characterization, and evaluation of a monoclonal antibody against the rabbit platelet glycoprotein IIb/IIIa in an experimental angioplasty model.

Discussion

Member takes

Implication

Study Design

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider